Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Harrison

Showing results (541-550 of 584) with videos related to

Pageof 59
Sort By:
Blood|November 19, 2005
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosisPeter J Campbell, Martin Griesshammer, Konstanze Döhner, et al.
Cancer Medicine|April 6, 2023
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studiesRuben A Mesa, Stacie Hudgens, Lysbeth Floden, et al.
Blood Advances|February 27, 2026
Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemiaHarinder Gill, Francesca Palandri, David M Ross, et al.
Blood Advances|May 7, 2025
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosisDavid M Ross, Florian H Heidel, Andrew C Perkins, et al.
British Journal of Haematology|December 1, 2023
The management of myelofibrosis: A British Society for Haematology GuidelineDonal P McLornan, Bethan Psaila, Joanne Ewing, et al.
American Journal of Hematology|September 6, 2023
A novel missense variant in ATP11C is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemiaMyrthe J van Dijk, Brigitte A van Oirschot, Alexander N Harrison, et al.
Obesity (Silver Spring, Md.)|October 15, 2013
Hepatic insulin clearance is the primary determinant of insulin sensitivity in the normal dogMarilyn Ader, Darko Stefanovski, Stella P Kim, et al.
Blood Advances|April 29, 2026
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 studyHarinder Gill, Abdulraheem Yacoub, Aaron T Gerds, et al.
Blood|February 21, 2014
Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patientsHolly L Geyer, Robyn M Scherber, Amylou C Dueck, et al.
Future Oncology (London, England)|August 11, 2022
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosisClaire N Harrison, Vikas K Gupta, Aaron T Gerds, et al.
Pageof 59

Showing results (541-550 of 584) with videos related to

Sort By:
Pageof 59
Blood|November 19, 2005
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosisPeter J Campbell, Martin Griesshammer, Konstanze Döhner, et al.
Cancer Medicine|April 6, 2023
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studiesRuben A Mesa, Stacie Hudgens, Lysbeth Floden, et al.
Blood Advances|February 27, 2026
Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemiaHarinder Gill, Francesca Palandri, David M Ross, et al.
Blood Advances|May 7, 2025
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosisDavid M Ross, Florian H Heidel, Andrew C Perkins, et al.
British Journal of Haematology|December 1, 2023
The management of myelofibrosis: A British Society for Haematology GuidelineDonal P McLornan, Bethan Psaila, Joanne Ewing, et al.
American Journal of Hematology|September 6, 2023
A novel missense variant in ATP11C is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemiaMyrthe J van Dijk, Brigitte A van Oirschot, Alexander N Harrison, et al.
Obesity (Silver Spring, Md.)|October 15, 2013
Hepatic insulin clearance is the primary determinant of insulin sensitivity in the normal dogMarilyn Ader, Darko Stefanovski, Stella P Kim, et al.
Blood Advances|April 29, 2026
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 studyHarinder Gill, Abdulraheem Yacoub, Aaron T Gerds, et al.
Blood|February 21, 2014
Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patientsHolly L Geyer, Robyn M Scherber, Amylou C Dueck, et al.
Future Oncology (London, England)|August 11, 2022
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosisClaire N Harrison, Vikas K Gupta, Aaron T Gerds, et al.
Pageof 59